Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening
2013
Background
Treatment for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is improving but not benefiting individuals unaware to be infected. To inform screening policies we assessed (1) the hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody (anti-HCV-Ab) prevalence for 34 European countries; and (2) the cost-effectiveness of screening for chronic HBV and HCV infection.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
173
References
173
Citations
NaN
KQI